The classification of AD proposed by the National Institute on Aging and Alzheimer's Association (NIA-AA) relies on biomarkers of amyloid (A), tau (T), and neurodegeneration (N) which constitute the ATN framework.1 Despite their diagnostic utility, these markers only capture a fraction of the intricate pathophysiology of AD. Here, MAPT is linked to Alzheimer disease.